Skip to main content

Advertisement

Table 6 Parameter values that have been specified via locally fitting the vascular tumour growth model to experimental data extracted from [62]

From: Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data

Cell line Experimental group λ 1 c d β p K 0 RMSE FOO
  day−1 mg/[day · mm3p · kg] day−1 · mm−2 mm3p - mm3 mm3  
HCT116 Control 0.2362 0.4884 0.0017 - - 194.5946 121.7580 7.35 · 10−1
Treatment 0.2362 0.3881 0.0017 1 5.7777 0.6 74.8503 6.61 · 10−2
(15 mg/kg)
HCP40 Control 0.1603 0.5036 0.0013 - - 223.3251 47.8814 1.30 · 10−1
Treatment 0.1233 0.0186 0.0013 0.9062 12.4022 17.2066 9.3102 8.76 · 10−5
(15 mg/kg)
HT29 Control 0.2138 0.5061 0.0017 - - 111.5735 58.1716 2.17 · 10−1
Treatment 0.2138 0.3783 0.0017 1 6.2774 0.6 129.8810 1.5 · 10−3
(15 mg/kg)
HP40 Control 0.2966 0.5056 0.0022 - - 134.0895 100.5007 3.77 · 10−1
Treatment 0.2966 0.4356 0.0022 1 4.5576 23.0272 93.2413 1.33 · 10−1
(15 mg/kg)
  1. First-order optimality (FOO) is a measure of the closeness of the solution to the optimum